OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Showing 14 citing articles:
Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Integrating CRISPR Technology with Key Genetic Markers in Pancreatic Cancer: A New Frontier in Targeted Therapies
Dimitrios Stefanoudakis
SynBio (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access
Dimitrios Stefanoudakis
SynBio (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine
Ziyi Zhu, John Paul Shen, Paul Chi-Lui Ho, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Ziyi Zhu, John Paul Shen, Paul Chi-Lui Ho, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism
Eduardo Ibello, Federica Saracino, Donatella Delle Cave, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Eduardo Ibello, Federica Saracino, Donatella Delle Cave, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 2
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 2
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
Eszter Molnár, Marcell Baranyi, Krisztina Andrea Szigeti, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 1
Eszter Molnár, Marcell Baranyi, Krisztina Andrea Szigeti, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 1
Mechanotransduction Circuits in Human Pathobiology
Antonios N. Gargalionis, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3816-3816
Open Access | Times Cited: 1
Antonios N. Gargalionis, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3816-3816
Open Access | Times Cited: 1
Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
A. Domínguez, M Perz, Yi Xu, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3564-3564
Open Access | Times Cited: 1
A. Domínguez, M Perz, Yi Xu, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3564-3564
Open Access | Times Cited: 1
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses
Megan Cole, Panayiotis Anastasiou, Claudia Lee, et al.
Science Advances (2024) Vol. 10, Iss. 44
Open Access | Times Cited: 1
Megan Cole, Panayiotis Anastasiou, Claudia Lee, et al.
Science Advances (2024) Vol. 10, Iss. 44
Open Access | Times Cited: 1
Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer
Gareth Pollin, Gwen Lomberk, Angela Mathison, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 4, pp. 1996-2001
Open Access
Gareth Pollin, Gwen Lomberk, Angela Mathison, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 4, pp. 1996-2001
Open Access
Immune-oncology potential of KRAS inhibitors
Míriam Molina‐Arcas, Jesse Boumelha, Julian Downward
Elsevier eBooks (2024), pp. 443-462
Closed Access
Míriam Molina‐Arcas, Jesse Boumelha, Julian Downward
Elsevier eBooks (2024), pp. 443-462
Closed Access
